Skip to content

Study · Animal study (in vivo) · mouse · 2013

3 results

Genetic and pharmacological mouse models of chronic melanocortin activation show enhanced baroreflex control of heart rate.

Rinne P, Harjunpää J, Mäkelä S, Savontaus E

Regulatory peptides14 Jan 2013Cited by 3 (Europe PMC)

PMID23327996 (opens in a new tab)DOI10.1016/j.regpep.2012.12.002 (opens in a new tab)PepBankPUB-23327996
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice, 7 days of MT-II treatment did not change 24-h mean arterial pressure or heart rate.

    In plain wordsIn mice, a week of melanotan II treatment did not change 24-hour blood pressure or heart rate.

    Peptide
    Melanotan II
    Outcome
    No significant change24-h mean arterial pressure and heart rate after chronic MT-II
    Study

    mousen: not reported in source

    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    0.3 mg/kg/day · intraperitoneal · 7 daysAs given in this study (mouse).

    Source sentences

    Summary
    Chronic treatment with MT-II did not change 24-h MAP or HR
    1 context sentence
    Summary · context
    Here we investigated the impact of chronic melanocortin activation on cardiovascular and autonomic nervous system functions by studying α- and γ-MSH overexpressing (MSH-OE) mice and, as pharmacological model, mice treated with the stable α-MSH analogue melonotan-II (MT-II, 0.3 mg/kg/day for 7 days, i.p.).
  2. 02AnimalAnimal study (in vivo)Mechanism

    In mice, MT-II had acute pressor and tachycardic actions.

    In plain wordsIn mice, melanotan II briefly raised blood pressure and heart rate right after a dose.

    Peptide
    Melanotan II
    Outcome
    IncreaseAcute pressor and tachycardic actions of MT-II
    Study

    mousen: not reported in source

    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    regardless of the acute pressor and tachycardic actions of MT-II.
    1 context sentence
    Summary · context
    Here we investigated the impact of chronic melanocortin activation on cardiovascular and autonomic nervous system functions by studying α- and γ-MSH overexpressing (MSH-OE) mice and, as pharmacological model, mice treated with the stable α-MSH analogue melonotan-II (MT-II, 0.3 mg/kg/day for 7 days, i.p.).
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In mice, MT-II treatment enhanced the heart rate response to vasodilatation, as seen in MSH-overexpressing mice.

    In plain wordsIn mice, melanotan II treatment strengthened the heart rate response to widened blood vessels.

    Peptide
    Melanotan II
    Outcome
    IncreaseHeart rate response to vasodilatation after MT-II
    Study

    mousen: not reported in source

    Outcome group
    Heart function · Cardiovascular
    Studied dose
    0.3 mg/kg/day · intraperitoneal · 7 daysAs given in this study (mouse).

    Source sentences

    Summary
    Consistent with the finding in MSH-OE mice, MT-II-treated mice showed an enhanced HR response to vasodilatation.
    1 context sentence
    Summary · context
    Here we investigated the impact of chronic melanocortin activation on cardiovascular and autonomic nervous system functions by studying α- and γ-MSH overexpressing (MSH-OE) mice and, as pharmacological model, mice treated with the stable α-MSH analogue melonotan-II (MT-II, 0.3 mg/kg/day for 7 days, i.p.).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 09:43 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.